Pfizer Announces Executive and Board Changes

Ticker: PFE · Form: 8-K · Filed: 2024-07-26T00:00:00.000Z

Sentiment: neutral

Topics: executive-changes, board-appointment, leadership-transition

Related Tickers: PFE

TL;DR

Pfizer's CSO is stepping down, new CSO appointed, and a new board member joins. Big pharma shuffle.

AI Summary

On July 24, 2024, Pfizer Inc. announced changes in its executive leadership and board of directors. Dr. Mikael Dolsten will transition from his role as Chief Scientific Officer to a Senior Advisor role, effective August 1, 2024, and will be succeeded by Dr. Arpa S. Garber. Additionally, Mr. Ronald A. Rittenmeyer Jr. has been appointed to the Board of Directors.

Why It Matters

These leadership transitions and board appointments could signal shifts in Pfizer's strategic direction and scientific focus, potentially impacting its future drug development and market performance.

Risk Assessment

Risk Level: medium — Leadership changes and board appointments can introduce uncertainty regarding future strategy and execution, impacting investor confidence.

Key Players & Entities

FAQ

Who is succeeding Dr. Mikael Dolsten as Chief Scientific Officer?

Dr. Arpa S. Garber is succeeding Dr. Mikael Dolsten as Chief Scientific Officer.

When is Dr. Mikael Dolsten's transition to Senior Advisor effective?

Dr. Mikael Dolsten's transition to Senior Advisor is effective August 1, 2024.

Has Pfizer appointed any new members to its Board of Directors?

Yes, Mr. Ronald A. Rittenmeyer Jr. has been appointed to the Board of Directors.

What was the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is July 24, 2024.

What is Pfizer Inc.'s principal executive office address?

Pfizer Inc.'s principal executive office is located at 66 Hudson Boulevard East, New York, New York 10001-2192.

From the Filing

0000078003-24-000144.txt : 20240726 0000078003-24-000144.hdr.sgml : 20240726 20240726110920 ACCESSION NUMBER: 0000078003-24-000144 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20240724 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240726 DATE AS OF CHANGE: 20240726 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 241144546 BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 8-K 1 pfe-20240724.htm PFIZER 8-K JULY 24 2024 pfe-20240724 0000078003 false 0000078003 2024-07-24 2024-07-24 0000078003 us-gaap:CommonStockMember 2024-07-24 2024-07-24 0000078003 pfe:NotesDue20271.000Member 2024-07-24 2024-07-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 24, 2024 PFIZER INC . (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) Identification No.) incorporation)     66 Hudson Boulevard East 10001-2192 New York, New York (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 212 ) 733-2323 (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☒ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $.05 par value PFE New York Stock Exchange 1.000% Notes due 2027 PFE27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Modifications to Five-Year Total Shareholder Return Units and Performance Share Awards As disclosed in Item 8.01 of this Current Report, the Compensation Committee of our Board of Directors approved modifications to outstanding Five-Year Total Shareholder Return

View on Read The Filing